drugset / Trial / NCT03509012
Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, multicenter, phase I study to evaluate the safety and tolerability of durvalumab ± tremelimumab in combination with chemoradiation in patients with advanced solid tumors
Timeline
- Start
- 2018-05-02
- Primary completion
- 2020-12-31
- Completion
- 2025-01-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Cisplatin | Other / unclassified | — | — |
| Subject | Durvalumab | Monoclonal antibody | — | Intravenous |
| Subject | Etoposide | Small molecule | — | — |
| Subject | Paclitaxel | Small molecule | — | — |
| Subject | Pemetrexed | Small molecule | — | — |
| Subject | Tremelimumab | Monoclonal antibody | — | — |